Nutrition & Celiac Disease
Enteral/parenteral nutrition and gluten-related disorders.
Nutrition support in 2027 emphasizes early enteral feeding in critical illness, ESPEN-aligned protein targets, and structured home parenteral nutrition programs with teduglutide for intestinal failure. Celiac disease pharmacotherapy is finally moving beyond the gluten-free diet, with the transglutaminase 2 inhibitor ZED1227 demonstrating mucosal protection in phase 2 and latiglutenase, IMGX003, and AMG 714 (anti-IL-15) advancing through trials. Sessions cover non-responsive and refractory celiac disease, enteropathy-associated T-cell lymphoma surveillance, micronutrient deficiencies after bariatric surgery, and the metabolic management of obesity with GLP-1 and dual incretin agonists.
- ZED1227 (TG2 inhibitor) and latiglutenase in celiac disease
- Refractory celiac disease and EATL surveillance
- Anti-IL-15 (AMG 714) and immunomodulators for celiac
- Home parenteral nutrition and teduglutide in short bowel syndrome
- Post-bariatric micronutrient deficiencies and surveillance
- GLP-1/GIP dual agonists: tirzepatide, retatrutide in obesity
- ESPEN protein and energy targets in critical illness